REPROS' PROMISING DRUG PIPELINE

Little- known Repros Therapeutics (RPRX) is expected to team up with a big drugmaker to help develop its lead product, Proellex, now in Phase III clinical trials, to treat uterine fibroids and related anemia--a $3 billion market. Each year "some 300,000 women in the U.S. undergo hysterectomy as a result of uterine fibroids," notes Mark Lappe, managing partner at Efficacy Capital, which owns shares. Repros is also developing Androxal, now in Phase II trials, to restore pituitary response in men with low testosterone levels, and for obese people with high blood pressure and diabetes. Lappe says 13 million men in the U.S. have testosterone deficiency. Oppenheimer analyst Dr. Brian Abrahams rates Repros, now at 9.64, outperform with a 12-month target of 19. "Proellex could fill an unmet need in treating fibroids," he says.

Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.